549 related articles for article (PubMed ID: 3356000)
1. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
2. Effect of mouse hepatitis virus infection on combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; DeKoning TF; Nicholas JA; Kramer GD; Wilson D; Wallace TL; Collins MJ
Lab Anim Sci; 1987 Feb; 37(1):41-4. PubMed ID: 3035278
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
Li LH; Johnson MA; Moeller RB; Wallace TL
Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
[TBL] [Abstract][Full Text] [Related]
4. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of pyrimidinones, a class of small-molecule biological response modifiers.
Li LH; Wallace TL; Wierenga W; Skulnick HI; DeKoning TF
J Biol Response Mod; 1987 Feb; 6(1):44-55. PubMed ID: 3559628
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
9. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Einstein AB; Fass L; Fefer A
Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
[TBL] [Abstract][Full Text] [Related]
10. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
14. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
15. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
16. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
Robak T; Szmigielska A
Neoplasma; 2000; 47(3):168-71. PubMed ID: 11043840
[TBL] [Abstract][Full Text] [Related]
18. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
19. [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
Uchida T; Nishikawa K; Shibasaki C; Okamoto K; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2275-82. PubMed ID: 2735770
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts.
Carmichael J; Fergusson RJ; Wolf CR; Balkwill FR; Smyth JF
Cancer Res; 1986 Oct; 46(10):4916-20. PubMed ID: 3019517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
